Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

Front Med (Lausanne). 2023 Jul 26:10:1256685. doi: 10.3389/fmed.2023.1256685. eCollection 2023.

Authors

Ningning Yan^#¹, Ziheng Zhang^#¹, Sanxing Guo¹, Shujing Shen², Xingya Li¹

Affiliations

¹ Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fmed.2023.1130012.].

Keywords: MET; MET-TKI; liver cancer; savolitinib; tyrosine kinase inhibitors.

Copyright © 2023 Yan, Zhang, Guo, Shen and Li.

Publication types

Published Erratum